Skip to main content

Advertisement

SpringerLink
Log in

Steroid-resistant nephrotic syndrome: a persistent challenge for pediatric nephrology

  • Educational Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Steroid-resistant nephrotic syndrome remains a challenge to treat, but various efforts are underway to better understand the pathogenesis and improve patient outcomes. This review provides an update on the newer advances in understanding the molecular etiologies for a variety of podocyte abnormalities, potential circulating factors that may initiate and sustain the steroid-resistant state, genetic mutations, and precision medicine treatment modalities in this continuously perplexing disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, Putaala H, Ruotsalainen V, Morita T, Nissinen M, Herva R, Kashtan CE, Peltonen L, Holmberg C, Olsen A, Tryggvason K (1998) Positionally cloned gene for a novel glomerular protein—nephrin—is mutated in congenital nephrotic syndrome. Mol Cell 1:575–582

    Article  CAS  PubMed  Google Scholar 

  2. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C (2000) NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24:349–354

    Article  CAS  PubMed  Google Scholar 

  3. Hinkes B, Wiggins RC, Gbadegesin R, Vlangos CN, Seelow D, Nurnberg G, Garg P, Verma R, Chaib H, Hoskins BE, Ashraf S, Becker C, Hennies HC, Goyal M, Wharram BL, Schachter AD, Mudumana S, Drummond I, Kerjaschki D, Waldherr R, Dietrich A, Ozaltin F, Bakkaloglu A, Cleper R, Basel-Vanagaite L, Pohl M, Griebel M, Tsygin AN, Soylu A, Muller D, Sorli CS, Bunney TD, Katan M, Liu J, Attanasio M, O'Toole JF, Hasselbacher K, Mucha B, Otto EA, Airik R, Kispert A, Kelley GG, Smrcka AV, Gudermann T, Holzman LB, Nurnberg P, Hildebrandt F (2006) Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 38:1397–1405

    Article  CAS  PubMed  Google Scholar 

  4. Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O, Miner JH, Shaw AS (1999) Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 286:312–315

    Article  CAS  PubMed  Google Scholar 

  5. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, Rosenberg PB (2005) A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308:1801–1804

    Article  CAS  PubMed  Google Scholar 

  6. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, Pollak MR (2000) Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24:251–256

    Article  CAS  PubMed  Google Scholar 

  7. Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, Striegel JE, Houghton DC, Junien C, Habib R, Fouser L, Fine RN, Silverman BL, Haber DA, Housman D (1991) Germline mutations in the Wilms’ tumor suppressor gene are associated with abnormal urogenital development in Denys–Drash syndrome. Cell 67:437–447

    Article  CAS  PubMed  Google Scholar 

  8. Barbaux S, Niaudet P, Gubler MC, Grunfeld JP, Jaubert F, Kuttenn F, Fekete CN, Souleyreau-Therville N, Thibaud E, Fellous M, McElreavey K (1997) Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 17:467–470

    Article  CAS  PubMed  Google Scholar 

  9. Zenker M, Aigner T, Wendler O, Tralau T, Muntefering H, Fenski R, Pitz S, Schumacher V, Royer-Pokora B, Wuhl E, Cochat P, Bouvier R, Kraus C, Mark K, Madlon H, Dotsch J, Rascher W, Maruniak-Chudek I, Lennert T, Neumann LM, Reis A (2004) Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet 13:2625–2632

    Article  CAS  PubMed  Google Scholar 

  10. Wang L, Ellis MJ, Gomez JA, Eisner W, Fennell W, Howell DN, Ruiz P, Fields TA, Spurney RF (2012) Mechanisms of the proteinuria induced by Rho GTPases. Kidney Int 81:1075–1085

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Gee HY, Saisawat P, Ashraf S, Hurd TW, Vega-Warner V, Fang H, Beck BB, Gribouval O, Zhou W, Diaz KA, Natarajan S, Wiggins RC, Lovric S, Chernin G, Schoeb DS, Ovunc B, Frishberg Y, Soliman NA, Fathy HM, Goebel H, Hoefele J, Weber LT, Innis JW, Faul C, Han Z, Washburn J, Antignac C, Levy S, Otto EA, Hildebrandt F (2013) ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. J Clin Invest 123(8):3243–3253

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hoyer JR, Vernier RL, Najarian JS, Raij L, Simmons RL, Michael AF (2001) Recurrence of idiopathic nephrotic syndrome after renal transplantation. J Am Soc Nephrol 12:1994–2002

    CAS  PubMed  Google Scholar 

  13. Artero ML, Sharma R, Savin VJ, Vincenti F (1994) Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 23:574–581

    Article  CAS  PubMed  Google Scholar 

  14. Zimmerman SW (1984) Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol 22:32–38

    CAS  PubMed  Google Scholar 

  15. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F (1996) Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334:878–888

    Article  CAS  PubMed  Google Scholar 

  16. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17(8):952–960

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Blasi F, Carmeliet P (2002) uPAR: A versatile signaling orchestrator. Nat Rev Mol Cell Biol 3:932–943

    Article  CAS  PubMed  Google Scholar 

  18. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F (1998) The level of urokinase-type plasminogen activator receptor is increased in the serum of ovarian cancer patients. Cancer Res 58:1843–1849

    CAS  PubMed  Google Scholar 

  19. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, Eugen-Olsen J l (2000) Serum levels of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96:4091–4095

    CAS  PubMed  Google Scholar 

  20. Meijers B, Maas R, Sprangers B, Claes K, Poesen R, Bammens B, Naesens M, Deegens J, Dietrich R, Storr M, Wetzels J, Evenepoel P, Kuypers D (2014) The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 85:636–640

    Article  CAS  PubMed  Google Scholar 

  21. Bock ME, Price HE, Gallon L, Langman CB (2013) Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol 8:1304–1311

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Hinkes BG, Mucha B, Vlangos CN, Gbadegesin R, Liu J, Hasselbacher K, Hangan D, Ozaltin F, Zenker M, Hildebrandt F (2007) Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 119:e907–e919

    Article  PubMed  Google Scholar 

  23. Beata S, Lipska BS, Iatropoulos P, Maranta R, Caridi G, Ozaltin F, Anarat A, Balat A, Gellermann J, Trautmann A, Erdogan O, Saeed B, Emre S, Bogdanovic R, Azocar M, Balasz-Chmielewska I, Benetti E, Caliskan S, Mir S, Melk A, Ertan P, Baskin E, Jardim H, Davitaia T, Wasilewska A, Drozdz D, Szczepanska M, Jankauskiene A, Higuita L, Ardissino G, Ozkaya O, Kuzma-Mroczkowska E, Soylemezoglu O, Ranchin B, Medynska A, Tkaczyk M, Peco-Antic A, Akil I, Jarmolinski T, Firszt-Adamczyk A, Dusek J, Simonetti GD, Gok F, Gheissari A, Emma F, Krmar RT, Fischbach M, Printza N, Simkova E, Mele C, Ghiggeri GM, Schaefer F, the PodoNet Consortium (2013) Genetic screening in adolescents with steroid resistant nephrotic syndrome. Kidney Int 84:206–213

    Article  Google Scholar 

  24. McCarthy HJ, Bierzynska A, Wherlock M, Ognjanovic M, Kerecuk L, Hegde S, Feather S, Gilbert RD, Krischock L, Jones C, Sinha MD, Webb N, Christian M, Williams MM, Marks S, Koziell A, Welsh GI, Saleem MA (2013) Simultaneous sequencing of 24 genes associated with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 8:637–648

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Santín S, Bullich G, Tazon-Vega B, García-Maset R, Gimenez I, Silva I, Ruíz P, Ballarín J, Torra R, Ars E (2011) Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 6:1139–1148

    Article  PubMed  PubMed Central  Google Scholar 

  26. Benoit G, Machuca E, Antignac C (2010) Hereditary nephrotic syndrome: a systematic approach for genetic testing and a review of associated podocyte gene mutations. Pediatr Nephrol 25:1621–1632

    Article  PubMed  PubMed Central  Google Scholar 

  27. Gbadegesin RA, Winn MP, Smoyer WE (2013) Genetic testing in nephrotic syndrome—challenges and opportunities. Nat Rev Nephrol 9:179–184

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Gellermann J, Constantinos J, Stefanidis CJ, Mitsioni A, Querfeld U (2010) Successful treatment of steroid-resistant nephrotic syndrome associated with WT1 mutations. Pediatr Nephrol 25:1285–1289

    Article  PubMed  Google Scholar 

  29. Hinkes B, Wiggins RC, Gbadegesin R, Vlangos CN, Seelow D, Nurnberg G, Garg P, Verma R, Chaib H, Hoskins BE, Ashraf S, Becker C, Hennies HC, Meera Goyal M, Wharram BL, Schachter AD, Mudumana S, Drummond I, Kerjaschki D, Waldherr R, Dietrich A, Ozaltin F, Bakkaloglu A, Cleper R, Basel-Vanagaite L, Pohl M, Griebel M, Tsygin AN, Alper Soylu A, Muller D, Sorli CS, Bunney TD, Katan M, Liu J, Attanasio M, O’Toole JF, Hasselbacher K, Mucha B, Otto EA, Airik R, Kispert A, Kelley GG, Smrcka AV, Gudermann T, Holzman LB, Nurnberg P, Hildebrandt F (2006) Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 38(12):1397–1405

    Article  CAS  PubMed  Google Scholar 

  30. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14:931–938

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Nijenhuis T, Sloan AJ, Hoenderop J, Flesche J, van Goor H, Kistler AD, Bakker M, Bindels R, de Boer RA, Möller CC, Hamming I, Navis G, Wetzels J, Berden J, Reiser J, Faul C, van der Vlag J (2011) Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol 179(4):1719–1732

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento SM, McMahan JL, Siegel N, D’Agati VD, Friedman AL (2011) Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 80:868–878

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Hogg RJ, Friedman A, Greene T, Radeva M, Budisavljevic MN, Gassman J, Gipson DS, Jefferson JA, John EG, Kaskel FJ, Moudgil A, Moxey-Mims M, Ortiz LA, Schelling JR, Schnaper W, Srivastava T, Trachtman H, Vehaskari VM, Wong C, Woronieki RP, Van Why SK, Zolotnitskaya A (2013) Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS. Clin J Am Soc Nephrol 8:211–218

    Article  CAS  PubMed  Google Scholar 

  34. D’Agati VD, Alster JM, Jennette JC, Thomas DB, Pullman J, Savino DA, Cohen AH, Gipson DS, Gassman JJ, Radeva MK, Moxey-Mims MM, Friedman AL, Kaskel FJ, Trachtman H, Alpers CE, Fogo AB, Greene TH, Nast CC (2013) Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol 8:399–406

    Article  PubMed  Google Scholar 

  35. Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384(9950):1273–1281

    Article  CAS  PubMed  Google Scholar 

  36. Bagga A, Sinha A, Moudgil A (2007) Rituximab in patients with steroid resistant nephrotic syndrome. N Engl J Med 356(26):2751–2752

    Article  CAS  PubMed  Google Scholar 

  37. Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, Benetti E, Murtas C, Messina G, Massella L, Porcellini MG, Montagna M, Regazzi M, Scolari F, Ghiggeri G (2012) Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 23:1117–1124

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Kamei K, Okada M, Sato M, Fujimaru T, Ogura M, Nakayama M, Kaito H, Iijima K, Ito S (2014) Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome. Pediatr Nephrol 29(7):1181–1187

    Article  PubMed  Google Scholar 

  39. Kemper MJ, Meyer-Jark T, Lilova M, Muller-Wiefel DE (2003) Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol 60:242–247

    Article  CAS  PubMed  Google Scholar 

  40. Stroopinsky D, Katz T, Rowe JM, Melamed D, Avivi I (2012) Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother 61:1233–1241

    Article  CAS  PubMed  Google Scholar 

  41. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd (2011) Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3:85ra46

    Article  PubMed  PubMed Central  Google Scholar 

  42. Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M (2008) Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 151:288–292

    Article  CAS  PubMed  Google Scholar 

  43. De Smet E, Rioux JP, Ammann H, Deziel C, Querin S (2009) FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrol Dial Transplant 24:2938–2940

    Article  PubMed  Google Scholar 

  44. Sgambat K, Banks M, Moudgil A (2013) Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome. Pediatr Nephrol 28:2131–2135

    Article  PubMed  Google Scholar 

  45. Trachtman H, Vento S, Gipson D, Wickman L, Gassman J, Joy M, Savin V, Somers M, Pinsk M, Greene T (2011). Novel Therapies for resistant focal segmental glomerulosclerosis (FONT2) phase II clinical trial: study design. BMC Nephrol 12:8. doi: 10.1186/1471-2369-12-8

  46. Ortiz A, Bustos C, Alonso J, Alcazar R, Lopez-Armada MJ, Plaza JJ, Gonzalez E, Egido J (1995) Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. Adv Nephrol Necker Hosp 24:53–77

    CAS  PubMed  Google Scholar 

  47. Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H (2010) Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): Report of the FONT (Novel Therapies for Resistant FSGS) Study Group. Am J Kidney Dis 55(1):55–60

    Article  Google Scholar 

  48. Chih-Chuan Yu C, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang J, Chen H, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW, Mundel P (2013) Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369(25):2416–2423

    Article  PubMed  PubMed Central  Google Scholar 

  49. Benigni A, Gagliardini E, Remuzzi G (2014) Comment in Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 370(13):1261–1263

  50. Garin EH, Reiser J, Cara-Fuentes G, Wei C, Matar D, Wang H, Alachkar N, Johnson RJ (2015) Case series: CTLA4–IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatr Nephrol 30(3):469–477

    Article  PubMed  Google Scholar 

  51. Barnett HL, Forman CW, McNamara H, McCrory WW, Rapoport M, Michie AJ, Barbero G (1951) The effect of adrenocorticotrophic hormone on children with the nephrotic syndrome. II. Physiologic observations on discrete kidney functions and plasma volume. J Clin Invest 30(2):227–235

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, Appel GB, Radhakrishnan J, Lafayette RA (2013) Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol 8(12):2072–2081

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Nephrology, Department of Pediatrics, Connecticut Children’s Medical Center, 282 Washington Street, Hartford, CT, 06095, USA

    Samriti Dogra

  2. Division of Pediatric Nephrology, Department of Pediatrics, Children’s Hospital at Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

    Frederick Kaskel

Authors
  1. Samriti Dogra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frederick Kaskel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samriti Dogra.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Sources of funding

Supported by NIH grant T32 DK007110.

Additional information

Answers

1. c (a cellular receptor for urokinase); 2. a (stabilizes SMPDL-3b in human differentiated podocytes); 3. d (none of the above) 4. d (all of the above); 5. c (statistically significant results were not attained secondary to small sample size)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dogra, S., Kaskel, F. Steroid-resistant nephrotic syndrome: a persistent challenge for pediatric nephrology. Pediatr Nephrol 32, 965–974 (2017). https://doi.org/10.1007/s00467-016-3459-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-016-3459-5

Keywords

Search

Navigation